Dopamine-agonist cabergoline (CB) reduces prolactin (PRL) secretion and tumor size in 80% of patients with prolactin-secreting adenomas (PRL-omas) by binding type 2 dopamine receptor (DRD2). The mechanisms responsible for resistance to CB remain largely unknown. To assess the association of DRD2 with sensitivity to CB, TaqI-A1/A2, TaqI-B1/B2, HphI-G/T and NcoI-C/T genotypes were determined in a cross-sectional retrospective study, including 203 patients with PRL-oma. DRD2 alleles frequencies did not differ between patients and 212 healthy subjects. Conversely, NcoI-T allele frequency was higher in resistant rather than responsive patients, considering both PRL normalization (56.6 vs 45.3%, P ¼ 0.038) and tumor shrinkage (70.4 vs 41.4%, P ¼ 0.006). Finally, [TaqI A1À/TaqI B1À/HphI TÀ/NcoI TÀ] haplotype was found in 34.5% of patients normalizing PRL with p3 mg/ week of CB vs 11.3% of resistants (P ¼ 0.021). In conclusion, resistance to CB was associated with DRD2 NcoI-T þ allele, consistent with evidence suggesting that this variant may lead to reduction and instability of DRD2 mRNA or protein.
Introduction
Prolactin-secreting pituitary adenomas (PRL-omas) are rare and well-differentiated tumors constituted by lactotroph cells with an estimated incidence of 6-10 cases per million per year. 1 The first-choice treatment of patients with PRL-omas is the dopamine agonist cabergoline (CB), a lysergic acid amide derivative, which is a potent type 2 dopamine receptor (DRD2) agonist and causes less side effects and a better pharmacological profile than other dopamine agonists. Resistance to CB, defined as failure to normalize PRL levels and/or to reduce tumor size, is reported in 10-15% of patients with PRL-omas. 2 Reduction of dopaminergic binding sites, decreased expression of DRD2 mRNA and a relative decrease in Gai expression have been described in resistant PRL-omas, as well as reduced levels of the short receptor isoform. [3] [4] [5] Finally, no mutations in the DRD2 gene have been so far described in PRL-omas resistant to medical treatment. 6 Multiple alternative splicing, including that occurring in exon 6 and generating the two major long and short isoforms, have been described for the DRD2. 7, 8 Moreover, there are several single nucleotide polymorphisms of the DRD2 gene that have mostly synonymous changes. Due to the critical role of dopaminergic activity in the central nervous system, several studies examined the association between common polymorphisms of the DRD2 gene and behavioral traits, psychiatric and neurological diseases, such as schizophrenia, alcoholism, smoking, opioids and polysubstance abuse, and susceptibility to migraine. [9] [10] [11] [12] [13] [14] Accordingly, in vivo evidence supporting the potential functional significance of DRD2 variants has been accumulating. In particular, previous studies reported the association of DRD2 TaqI A, TaqI B and NcoI polymorphisms with modifications in D2 receptor binding and expression in human central nervous system, particularly in the striatum. [15] [16] [17] [18] The aim of this study was to assess the possible association between four common DRD2 gene polymorphisms (that is, TaqI A1/A2, TaqI B1/B2, HphI G/T and NcoI C/T) and the efficacy of CB treatment in patients with PRL-oma.
Results

Clinical data
Two hundred and three patients with PRL-omas (98 male and 105 female, mean age at diagnosis 36.6 ± 15.0 years) were enrolled in this retrospective cross-sectional study. As it is known that the size of the tumor is one of the major determinants of PRL levels, the study included a similar number of patients with either micro-or macro-PRL-oma (adenoma size o10 mm or X10 mm, respectively) consecutively seen by the different centers. Subsequently, about half (50.3%) of the patients had a macroadenoma. All patients had a clinical and hormonal reevaluation every 3-4 months and magnetic resonance imaging every 6-9 months. During follow-up (range: 18-38 months), the mean lowest dosage of CB required for PRL normalization and reduction of the tumor size was 1.40±1.13 mg/week, 45.3% patients requiring o1 mg/week. Twenty-two (10.8%) patients failed to normalize PRL levels with CB at the dosage of 43 mg/week after 3-4 months follow-up and were considered resistant. In this subset, 54.6% of patients were males, 68.2% had a macroadenoma and the median PRL was 452 ng/ml (interquartile range 257-12 230). Seventeen (8.4%) patients did not reduce tumor size at CB 43 mg/week. A discrepancy between hormonal and tumor size responses was observed in five patients with macroadenoma (three males and two females) in whom 43 mg/week of CB induced a tumor-size reduction from 60 to 75% without normalizing PRL levels. The increase of CB dosage to 4, 4.5, 5 and 9 mg/week in 17, 2, 2 and 1 patient, respectively, did not overcome the resistance in terms of PRL normalization and tumor-size reduction in any patient.
Genotype analysis in normal subjects and in patients with PRL-omas The four DRD2 polymorphisms were genotyped in 203 patients with PRL-oma and 212 healthy subjects. No statistically significant differences in genotypes and alleles proportions were found between the two groups (Table 1) . Due to the low prevalence of TaqI A1, TaqI B1, HphI T and NcoI T alleles, their homozygotes were grouped with relative heterozygotes, forming TaqI A1 þ , TaqI B1 þ , HphI T þ and NcoI T þ groups, respectively.
No association between DRD2 polymorphisms and sex, age at diagnosis and PRL levels was observed in patients with PRL-oma ( Genotype analysis in patients with PRL-omas and sensitivity to CB treatment When considering patients who achieved PRL normalization and tumor-size reduction under CB treatment (from 0.5 to 3 mg/week), no association between DRD2 polymorphisms and the effective CB dosage was observed. Similarly, no association between TaqI A, TaqI B and HphI polymorphisms and resistance to CB in terms of PRL and tumor size was found (Table 3) . By contrast, the prevalence of NcoI genotype was different in patients resistant to CB treatment in comparison with those who were responsive. In fact, NcoI T þ allele was identified in 56.6% (12/22) of patients resistant to CB and 45.3% (84/181) of those normalizing at CB p3 mg/week (Fisher's exact test, P ¼ 0.038) ( Table 3 ). In the group of patients with NcoI T allele, TT homozygotes were 36% in responsive subjects vs 50% in resistants and TC heterozygotes were 9 vs 4%, respectively.
This association was also found, considering the tumor shrinkage in response to CB, as NcoI T þ variant was present in 70.4% of patients (12/17) who did not reach a 430% tumor-size reduction at CB p3 mg/week vs 41.4% (77/186) in the responsive group (Fisher's exact test, P ¼ 0.006) ( Table  3 ). In the set of NcoI T allele carriers, TT homozygotes were 35% in responsive patients vs 65% in resistants, and TC heterozygotes were 7 vs 6%, respectively.
A multivariate logistic regression analysis has been carried out using backward method, considering failure to normalize PRL levels with CB at the dosage of 43 mg/week as dependent variable and with the following predictors: TaqI A þ , TaqI B þ , Hph T þ, NcoI T þ, PRL levels, presence of macroadenoma and age at diagnosis. Only NcoI Tþ genotype was a significant predictor of the unsuccessful normalization of PRL by CB therapy (odds ratio 5.181, 95% confidence interval 1.369-19.1645, P ¼ 0.015). As far as the failure in tumor shrinkage was considered, none of the above predictors were retained in the residual model.
Finally, haplotype analysis of DRD2 polymorphisms showed that [TaqI A1À/TaqI B1À/HphI TÀ/NcoI TÀ] combination was found in 34.5% of patients taking p3 mg/week to normalize PRL levels vs 11.3% of resistant patients (Fisher's exact test, P ¼ 0.021). Such association was not present when the effect on tumor shrinkage was evaluated.
Discussion
This study first investigated the presence of DRD2 polymorphisms in patients with PRL-omas and provided evidence for the association of the NcoI C/T polymorphism with resistance to CB in these patients. Emerging evidence suggests that, although most polymorphisms in the coding and noncoding regions are functionally neutral, some variations, even when synonymous, may have functional consequences. [19] [20] [21] Multiple polymorphisms as well as alternative splicing have been described in DRD2. As dopamine D2 receptor is involved in motor control, cognition and drug-related reward and reinforcement, DRD2 polymorphic variants have been extensively analyzed for disease-association studies, particularly focused on psychiatric/neurological phenotypes. [22] [23] [24] [25] [26] Moreover, some of these synonymous variations have been demonstrated to affect D2 receptor expression in central nervous system, particularly in the striatum and caudate nucleus. [15] [16] [17] [18] By contrast, although it is well established that defective dopamine signaling may result in PRL hypersecretion and lactotroph proliferation, 2 the possible association of DRD2 polymorphisms with PRL-omas has been so far disregarded. Indeed, the few studies investigating the possible relationships between PRL secretion and DRD2 variants focused on the impact of DRD2 polymorphisms on PRL levels in patients with schizophrenia during treatment with a variety of antipsychotic medications. 27 We focused our analysis on four frequent synonymous variations, TaqI A1/A2, TaqI B1/B2, HphI G/T and NcoI C/T, which have been thought to be associated with neuropsychiatric diseases, eating disorders and personality traits, although studies attempting to replicate these data frequently gave discordant results. In particular, Taq1 A1/A2 (located at 3 0 of DRD2 and recently reported to be a polymorphism of ankyrin repeat and kinase domain containing 1 ANKK1 gene) has been found to be associated with schizophrenia, severe alcoholism and other substance-use disorders as well as obesity. Similarly, TaqI B1/B2 (located in intron 1, 882 bp upstream exon 2) and HphI G/T (located in intron 6, 83 bp upstream exon 7) have been thought to be associated with alcohol and drug dependence, whereas Entries are expressed as number of cases, frequencies (95% confidence interval). Variables were compared using w 2 test.
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NcoI C/T (a synonymous cytosine to thymine transition at position 957) has been thought to be associated with schizophrenia and susceptibility to migraine. [9] [10] [11] [12] [13] [14] [22] [23] [24] [25] [26] By genotyping about 200 controls and patients with prolactinomas, we found similar allelic frequencies of TaqI A1/A2, TaqI B1/B2, HphI G/T and NcoI C/T in the two groups that were comparable to those of European and American populations (NCBI, Entrez SNP database, TaqI A: http:// www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs ¼ 1800497; TaqI B: http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs ¼ 1079597; HphI:
http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs ¼ 1076560; NcoI: http://www.ncbi.nlm.nih.gov/SNP/snp_ref. cgi?rs ¼ 6275). We then investigated the possible associations between the different genotypes and clinical and hormonal characteristics of patients. No statistically significant differences in genotype and allele proportions were found between the two groups, thus ruling out a role of receptor variants in prolactinoma development.
As far as the clinical phenotype of patients was concerned, no association between DRD2 polymorphisms and sex, age at diagnosis and PRL levels was observed in patients with PRL-oma. These data are at variance with a previous study investigating the impact of variants of somatostatin receptor isoforms and the clinical characteristics of patients with acromegaly. Indeed, in this cohort of patients, polymorphic variants of somatostatin receptor type 5 were associated with growth hormone and insulin like growth factor-I levels. 28 When we analyzed patients with prolactinoma according to the size of the adenoma, a strong linkage disequilibrium between TaqI A1À and HphI TÀ polymorphisms was found only in patients bearing microadenomas. Taking into account the association between TaqI A2 and HphI G alleles and high D2 dopamine receptor density in caudate nuclei samples reported previously, 29 these data are consistent with the notion that microadenomas are generally well responsive to CB therapy, 2 as also shown in this study. We then investigated the association of DRD2 polymorphisms with the responsiveness to cabergoline, a potent dopamine D2 receptor agonist that is currently the firstchoice treatment for patients with PRL-oma. As tumor size is one of the most important determinants of resistance to dopaminergic drugs, a similar number of patients with micro-and macroprolactinomas were genotyped according to the study protocol. Criteria for the definition of resistance to dopaminergic agents as well as the standard CB dose thresholds required for the assessment of this status are not clearly established. 2 For the purpose of this genotype/ phenotype analysis, patients were defined as resistant when they failed to normalize PRL levels taking 43 mg/week CB. In agreement with previous studies, 2 resistance to CB was observed in about 10% of patients and was associated with a lack of tumor-size reduction. Among resistant patients, patients with DRD2 NcoI T þ genotype, that is, homozygotes or heterozygotes for 957T allele, were significantly more frequent than patients with DRD2 NcoI TÀ, that is, homozygotes for C957. This association was further con- , was associated with a greater sensitivity to CB treatment in terms of PRL normalization. This is consistent with the notion that normalization of PRL levels and reduction in tumor mass are frequently concomitant events. DRD2 NcoI T þ genotype was also significantly associated with resistance to the antitumoral action of CB. The polymorphism examined by the restriction enzyme NcoI is a common synonymous cytosine to thymine transition at position 957 that has been associated previously with susceptibility to migraine and schizophrenia. 12, 30, 31 Interestingly, this polymorphism has been reported to have an endocrine correlate. 32 In fact, a recent study carried out on a cohort of subjects from the Sweden National Population Registry reported a high prevalence of 957T genotype in subjects with high systolic and diastolic blood pressure. On the basis of this association, the authors suggested that this variant might cause defective dopamine signaling, resulting in elevated blood pressure due to deficient inhibition of noradrenaline release from sympathetic nerve endings and aldosterone secretion from the adrenals. 32 Indeed, increasing in vitro and in vivo evidence indicates that this change in DRD2, though synonymous, has marked functional consequences. In particular, it has been demonstrated that 957T, rather than being silent, altered the predicted mRNA folding, leading to a decrease in mRNA stability and translation. 18 In fact, in DRD2-transfected CHO-K1 cells, the DRD2 mRNA carrying the 957T allele decayed significantly faster than mRNA carrying C957. This event resulted in a 50% decrease in the receptor synthesis. 18 Moreover, by investigating in vivo DRD2 binding in healthy subjects using [ 11 C]raclopride and PET (positron emission tomography), it has been demonstrated that subjects carrying the 957T allele had markedly lower striatal D2 receptor availability than those with C975. 17 It is therefore tempting to speculate that a similar reduction of D2 receptors in subjects with 957T allele may also occur at the pituitary level. In this respect, it would be of interest to test whether the only changes so far identified in PRL-omas removed from resistant patients, that is, reduction and instability of DRD2 mRNA or protein, [3] [4] [5] were associated with the presence of 957T variant.
In conclusion, this study suggests that 957T variant of DRD2 was associated with resistance to dopaminergic drugs in patients with PRL-oma. This in vivo neurobiological correlate further supports the view that C957T may have functional consequences and suggests that this polymorphism might be considered an interesting candidate for genetic predisposition studies in DRD2-associated neuroendocrinologic disorders. Further studies are needed to assess the clinical implication of genotyping patients with prolactinoma for DRD2 polymorphisms.
Materials and methods
Subjects
A computerized database was developed using Microsoft Access 2000 software (Microsoft Corporation, 1999), as described previously. 33 The database was divided into two parts: a principal table, including information about the patient at the time of recruitment, and several follow-up records. Each patient received an identification number, and personal information was available only to principal investigators or coinvestigators. Patients (n ¼ 203) with PRL-oma were collected in 11 Italian Endocrine and Neurosurgery Departments between 1998 and 2005. In Table 3 TaqI A, TaqI B, HphI and NcoI DRD2 polymorphisms in patients with PRL-oma responsive or resistant to cabergoline treatment in terms of prolactin normalization and tumor-size reduction
PRL normalization (% patients)
Tumor-size reduction (% patients) Patients who showed a 430% reduction of tumor size taking CB at the dosage of p3 mg/week were considered responsive. particular, the inclusion criteria were the following: (1) confirmed hyperprolactinemia by blood sample collections in supine patients during a slow saline infusion; (2) exclusion of macroprolactin by polyethylene glycol precipitation test; (3) no hyperprolactinemic drugs, pregnancy or major psychiatric illness; in particular, in all women estrogen was withdrawn before diagnosis and eventually restarted after PRL normalization during CB treatment in post-menopausal women; (4) evidence of pituitary adenoma at magnetic resonance imaging. All patients had a clinical and hormonal reevaluation every 3-4 months and magnetic resonance imaging every 6-9 months. CB treatment was started with 0.25-0.5 mg/week and the dosage was subsequently titrated up to 3 mg/week according to biochemical and tumor-size response, during periodical follow-up examinations. The criteria for responsiveness to the therapy were the following: (1) normalization of PRL levels at CB dosage of p3 mg/week; (2) reduction of the tumor size more than 30% at CB dosage of p3 mg/week, an arbitrary cutoff in the range of the proposed cutoffs (20-80) used in literature. 2 Finally, as it is known that the size of the tumor is one of the major determinants of PRL levels, the study included a similar number of patients with either micro-or macro-PRLoma consecutively seen by the different centers. As CB dosages used in these patients were definitely lower than 2-5 mg/day, a dosage reported to be responsible for cardiac valvulopathy in subjects affected with Parkinson disease, periodical ultrasound heart examination was not carried out. 34 Genotyping was performed on blood DNA from 212 sexmatched healthy subjects as controls. Written informed consent was obtained from all the participants in the study, and the study was approved by the Ethics Committee of Fondazione Ospedale Maggiore.
Prolactin assay
In the participating centers, immunoreactive PRL levels were measured in duplicate using the commercial assay kits reported below: PRL-CTK IRMA (Sorin Biomedica, Saluggia, Italy) with normality range 3-20 ng/ml in females and 3-13 ng/ml in males; PRL 1-step immunoluminometric sandwich assay using directly coated magnetic microparticles (DiaSorin, Saluggia, Italy) with normality range 5-25 ng/ml in females and 4-20 ng/ml in males; Delfia (PerkinElmer Inc., Waltham, MA, USA) with normality range 3-15 ng/ml in females and 2-10 ng/ml in males and RAD Prolactin (IRMA, Radim, Pomezia, Italy) with normality range 5-25 ng/ml in females and 5-15 ng/ml in males. Z-scores were calculated for each prolactin assay.
Genetic analysis
Blood samples were collected from the patients, and leukocyte DNA was extracted by Nucleon BACC2 genomic DNA purification kit (GE Healthcare, Piscataway, NJ, USA) in compliance with the manufacturer's instructions.
The following polymorphisms were analyzed: TaqI A1/A2 (rs1800497), located at the 3 0 of DRD2 and recently reported to be a polymorphism of ankyrin repeat and kinase domain containing 1 (ANKK1) gene; TaqI B1/B2 (rs1079597), localized in intron 1, 882 bp upstream of exon 2, causing an adenine to guanine transition; HphI G/T (rs1076560) located in intron 6, 83 bp upstream of exon 7, causing a guanine-to-thymine transversion; NcoI C/T (C957T, rs6275), causing a synonymous cytosine-to-thymine transition at the third nucleotide of the codon 313. The primers used to amplify TaqI A polymorphism were 5 0 -CCGTCGACGGCT GGCCAAGTTGTCTA-3 0 (forward) and 5 0 -CCGTCGACCCTT CCTGAGTGTCATCA-3 0 (reverse), whereas for TaqI B polymorphism the primers were 5 0 -GATACCCACTTCAG GAAGTC-3 0 (forward) and 5 0 -GATGTGTAGGAATTAGCCA GG-3 0 (reverse). HphI and NcoI polymorphisms were enclosed in one polymerase chain reaction (PCR) product by this primers pair: 5 0 -GGCATGGTCTGGATCTCA-3 0 (forward) and 5 0 -TGACCCTGTGGTGTTTGC-3 0 (reverse). PCRs were carried out in a 50-ml reaction mix with 0.8 U Taq DNA polymerase DyNAzyme (Finnzymes, Espoo, Finland) and subjected to denaturation at 95 1C for 5 min, followed by 35 cycles of 95 1C for 30 s, 58 1C for 30 s and 72 1C for 30 s. A final cycle at 72 1C for 5 min was carried out to allow complete extension of the amplified fragments. TaqI enzyme digestions were performed in 50 ml of reaction mix with 10 U of TaqI restriction enzyme (New England Biolabs, Ipswich, MA, USA) and 17.5 ml of PCR product. The reactions were incubated at 65 1C overnight. NcoI and HphI enzyme digestion were performed together in 50 ml of reaction mix with 2 U of NcoI and 2.5 U of HphI (New England Biolabs) and 17.5 ml of PCR product. The reactions were incubated at 37 1C overnight. Digestions were resolved on a 3% agarose gel.
Finally, 50 randomly selected samples underwent direct sequencing (primers and conditions used available upon request). In all cases, direct sequencing data confirmed the results of RFLP analysis.
Statistics
Quantitative variables were reported as mean±s.d. or as medians and interquartile ranges if variables were not normally distributed, unless otherwise indicated. Differences among means were evaluated by t-test, in agreement with normal distribution. Non-Gaussian variables were analyzed using Mann-Whitney test. w 2 analysis or Fisher's exact test was used to test the difference between categorical variables. Two-tailed P-value less than 0.05 was considered statistically significant. Multivariate logistic regression analysis was carried out with backward elimination method based on the likelihood-ratio statistic, using X0.10 as removal threshold. Po0.05 was considered to be a residual statistical significance. Calculations were performed by SPSS 11.0 software (SPSS, Paris, France). 
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